Dianthus Therapeutics (DNTH) AI Stock Analysis

• Market Cap: $3.46B
• Dividend Yield: N/A
• Average Volume (3M): 1.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: -42.64%
• EPS Growth: -39.78%
• Country: US
• Employees: 78
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.43
• Shares Outstanding: 44,471,092
• 10 Day Avg. Volume: 588,847
• 30 Day Avg. Volume: 1,003,841
• PEG Ratio: -0.15
• Price to Book (P/B): 3.16
• Price to Sales (P/S): 764.98
• P/FCF Ratio: -12.05
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 1.36K
• Enterprise Value/Gross Profit: 1.36K
• Enterprise Value/Ebitda: -15.93
• 1Y Price Target: $121.60
• Price Target Upside: 56.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): -4.33
• Revenue Forecast (FY): $1.75M

• Rating: 53 Neutral
• Price Target: $87.00 ▲(11.74% Upside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

Score is held down primarily by worsening losses and accelerating cash burn despite low leverage. Technicals show strong trend strength but are overextended, increasing pullback risk. Offsetting these negatives, major financing and positive Phase 3 progress improve runway and program momentum, while valuation remains constrained by ongoing losses.

Positive Factors

Low leverage / strong balance sheet

Extremely low reported leverage and a materially larger asset base enhance solvency and funding optionality. This structural strength reduces refinancing risk over the next 2–6 months, allowing the company to sustain clinical programs and absorb near-term operating losses without imminent liquidity stress.

Major equity offering bolsters runway

A large, executed public offering meaningfully extends cash runway and financial flexibility into multiple years, enabling continued late‑stage trials and parallel program advancement. This structural capital infusion reduces near-term fundraising pressure and supports execution of registrational plans.

Positive Phase 3 early GO decision

An early go decision in a Phase 3 registrational program materially de‑risks that asset and accelerates development timelines. It supports building a neuromuscular franchise, enables potential label and commercial planning, and improves long‑term strategic optionality across autoimmune indications.

Negative Factors

Rising cash burn

Operating and free cash flow deterioration reflects increased R&D and G&A spend to advance multiple programs. Persistently negative cash generation means reliance on external financing to fund operations, raising execution risk if capital markets tighten or fundraising terms worsen over the medium term.

No approved products / no meaningful revenue

Being clinical‑stage with no product revenue means the business lacks diversified, recurring cash inflows. The company’s ability to achieve self‑sustaining operations depends on successful trial outcomes and future commercialization, making financial stability contingent on binary clinical and regulatory events.

Widening losses and weak profitability

Sharply larger net losses and negative ROE indicate the existing capital base is not generating returns and that spending is outpacing any revenue scale. Over several quarters this weakens margin sustainability and increases dependence on dilution or partnerships to fund ongoing development.

Dianthus Therapeutics Business Overview & Revenue Model

Company Description

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

How the Company Makes Money

Dianthus Therapeutics does not appear to generate meaningful recurring revenue from product sales because its programs are in clinical development and it has no approved products. As a result, its operations are primarily funded through financing activities such as raising capital in the public markets (e.g., equity offerings) and other funding sources typical for clinical-stage biotech companies. Information on specific, material revenue-generating commercial partnerships, licensing income, or milestone/royalty streams is null.

Dianthus Therapeutics Financial Statement Overview

Summary

Financial profile is mixed but overall weak: revenue is small and volatile, losses widened sharply in 2025, and operating/free cash flow burn increased materially. The main offset is a strong, low-leverage balance sheet, which reduces near-term solvency risk but does not fix deteriorating profitability and cash usage.

Income Statement

Revenue remains small and volatile (down ~34% in 2025 vs. 2024 after prior swings), offering limited scale to absorb costs. Losses have widened materially in 2025 (net loss ~$162.3M vs. ~$84.9M in 2024), pointing to a sharply weaker profitability profile and heavier spending. While earlier years showed periods of higher gross profit, the overall earnings trajectory is clearly negative and deteriorating in the latest annual period.

Balance Sheet

The balance sheet is a relative strength: leverage is very low (debt-to-equity ~0.003 in 2025; total debt ~$1.4M against ~$493.4M equity), which reduces refinancing and solvency risk. Total assets increased meaningfully by 2025, supporting financial flexibility. The key weakness is consistently negative returns on equity (about -33% in 2025), reflecting that the capital base is not currently generating profits.

Cash Flow

Cash burn is substantial and rising: operating cash flow was about -$129.1M in 2025 versus -$78.2M in 2024, and free cash flow was similarly negative (~-$129.3M in 2025). Free cash flow was roughly in line with net loss, indicating losses are translating into real cash outflows rather than being largely non-cash. A modest improvement in free cash flow growth in 2025 (positive growth rate) is outweighed by the still-deep negative cash generation and escalating burn.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.04M	6.24M	2.83M	6.42M	1.48M
Gross Profit	2.04M	6.24M	2.83M	6.42M	1.48M
EBITDA	-177.93M	-101.45M	-47.82M	-29.56M	-13.09M
Net Income	-162.34M	-84.97M	-43.55M	-28.48M	-13.11M
Balance Sheet
Total Assets	530.92M	374.01M	179.41M	83.11M	189.93M
Cash, Cash Equivalents and Short-Term Investments	404.30M	275.24M	173.72M	75.49M	176.93M
Total Debt	1.39M	1.49M	585.00K	788.00K	0.00
Total Liabilities	37.52M	21.53M	10.54M	9.45M	17.26M
Stockholders Equity	493.40M	352.48M	168.87M	73.66M	172.67M
Cash Flow
Free Cash Flow	-129.27M	-78.28M	-36.97M	-29.21M	-60.80M
Operating Cash Flow	-129.06M	-78.18M	-36.86M	-29.07M	-59.53M
Investing Cash Flow	-122.83M	-286.81M	20.25M	-59.82M	43.43M
Financing Cash Flow	280.13M	255.62M	133.57M	96.68M	89.60M

Dianthus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 77.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Positive. The current price of 77.86 is above the 20-day moving average (MA) of 60.93, above the 50-day MA of 52.32, and above the 200-day MA of 35.53, indicating a bullish trend. The MACD of 8.48 indicates Negative momentum. The RSI at 70.20 is Negative, neither overbought nor oversold. The STOCH value of 81.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNTH.

Dianthus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EWTX	61 Neutral	$3.17B	-12.72	-31.97%	―	―	-5.73%
AMLX	55 Neutral	$1.55B	-7.89	-57.52%	―	-100.34%	52.85%
DNTH	53 Neutral	$3.46B	-9.59	-28.57%	―	-42.64%	-39.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JANX	50 Neutral	$826.09M	-7.53	-11.55%	―	-23.37%	-42.45%
ARDX	49 Neutral	$1.42B	-22.81	-40.63%	―	58.12%	24.08%
BHVN	45 Neutral	$1.44B	-1.64	-688.89%	―	―	18.76%

Dianthus Therapeutics Corporate Events

Dianthus Therapeutics Announces Major Public Equity Offering

On March 10, 2026, Dianthus Therapeutics, Inc. entered into an underwriting agreement with a syndicate of investment banks to launch a public offering of 7,313,582 shares of common stock at $81.00 per share and pre-funded warrants equivalent to 402,468 shares at $80.999 per share. The underwriters exercised in full a 30-day option on March 11, 2026 to purchase an additional 1,157,407 shares at the public offering price, less underwriting discounts and commissions.

The offering, conducted under an effective shelf registration and related SEC filings, is expected to close on March 12, 2026 and generate approximately $673.5 million in net proceeds for Dianthus Therapeutics after fees and expenses. The deal structure, including exercise caps on the pre-funded warrants and standard indemnification provisions for the underwriters, significantly bolsters the company’s capital base and financial flexibility while managing ownership concentration among investors.

The most recent analyst rating on (DNTH) stock is a Hold with a $92.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.

Dianthus Advances Claseprubart With Positive Phase 3 Update

On March 9, 2026, Dianthus Therapeutics reported fourth-quarter and full-year 2025 results and highlighted an early GO decision in its Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy, after meeting responder criteria with fewer than 40 planned participants in Part A. The company also outlined progress across its portfolio, including plans to start a Phase 3 registrational trial of claseprubart in generalized myasthenia gravis in mid-2026, ongoing Phase 2 work in multifocal motor neuropathy, and a Phase 1 program for DNTH212, supported by a $514.4 million cash position as of December 31, 2025 that extends its runway into 2028 despite a wider annual net loss driven by higher R&D and G&A spending.

The early CAPTIVATE decision strengthens Dianthus’s bid to build a leading neuromuscular franchise around claseprubart, which is designed for infrequent, self-administered subcutaneous dosing and aims to shift the standard of care in high unmet-need autoimmune diseases. For stakeholders, the combination of accelerated clinical momentum, expanding trials in gMG and MMN, and substantial liquidity underscores both the company’s growing investment in late-stage development and its capacity to advance multiple autoimmune programs in parallel, albeit with increased operating losses reflecting its intensified clinical activity in 2025.

The most recent analyst rating on (DNTH) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.